

ASSOCIATION OF BLOOD TYPE AND MORTALITY OF COVID-19: A HOSPITAL-BASED STUDY IN NATIONAL REFERRAL HOSPITAL, INDONESIA

USMAN Elly¹ and KATAR Yusticia¹

¹Department of Pharmacology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.

Corresponding Author's E-Mail: ellyusman@med.unand.ac.id

Article History

Received: Dec. 12th 2022

Revised Received: Feb. 11th 2022

Accepted: Feb. 17th 2022

Published Online: March 29th 2023

Abstract

Background: The ABO blood type is crucial in a number of illnesses, including cancer, cardiovascular disease, and some communicable and non-communicable illnesses. However, there is currently little clear evidence between COVID-19 with ABO blood types.

This study was, therefore, aimed to assess the association between ABO blood type and the mortality of patients infected with COVID-19 in a national referral hospital in Indonesia.

Materials and Methods: This study used a retrospective cohort design. The research sample was COVID-19 patients who were in Dr. M. Djamil Hospital Padang. The number of samples in this study was 93 subjects. The Chi-square test was used in the data analysis. The data were analyzed using the SPSS version 21.0 program, and $p < 0.05$ was considered significant.

Results: The results of this study found the percentage of mortality of COVID-19 patients was higher for blood group O (46.2%), followed by AB (41.7%), B (26.3%), and A (13.9%). There was a relationship between blood type and mortality in hospitalized COVID-19 patients ($p < 0.05$), where blood type O had the highest risk (OR = 5.31, 95% CI 1.57-17.98) followed by blood type AB (OR = 4.43, 95% CI 1.01-19.58).

Conclusion: This study confirmed there was a relationship between blood type and mortality in hospitalized COVID-19 patients, where blood type O had the highest risk followed by blood type AB.

Keywords: Blood type, COVID-19, Hospitalized, Mortality

List of Abbreviations: *CI*: Confidence interval; *COVID-19*: Coronavirus disease 2019; *ICU*: Intensive care unit; *OR*: Odds ratio; *SARS-CoV-1*: Severe acute respiratory syndrome coronavirus 1; *SARS-CoV-2*: Severe acute respiratory syndrome coronavirus 2; *vWF*: von Willebrand Factor.

Introduction

COVID-19 pandemic has taken a devastating impact on the world, regardless of age or gender, but especially on older persons who have co-morbid conditions including diabetes and cardiovascular and cerebrovascular disease (Almazeedi *et al.*, 2020; Velavan *et al.*, 2020). Indonesia has also faced a significant increase in COVID-19 patients which has resulted in morbidity and even death (Hikmawati *et al.*, 2021).

ABO blood type has been linked to the presence of COVID-19 infection in earlier studies. The ABO blood type is crucial in a number of illnesses, including cancer, cardiovascular disease, and some communicable and non-communicable illnesses (Fan *et al.*, 2020). Several studies have shown that having blood type O significantly lowers the chance of contracting hepatitis B (Mohammadali *et al.*, 2014; Belali, 2022). In addition, people with blood type A are more likely to develop rotavirus gastroenteritis than patients with blood type B (Mohammadali *et al.*, 2014; Elnady *et al.*, 2017). In addition, it was found that those with blood type AB are 2.5 times more likely than people with other blood types to contract dengue fever (Muruganathan *et al.*, 2018). Previous research on SARS-CoV-1 has found a correlation between blood type and the risk of infection, with people with group O blood having a small chance of SARS-CoV-1 infection (Cheng *et al.*, 2005).

There has not been much conclusive evidence to date between SARS-CoV-2 and ABO blood types (Zhao *et al.*, 2021). According to the majority of research, blood type O has a lower probability of developing severe SARS-CoV-2 infection than blood type A, which has a higher risk of infection (Goker *et al.*, 2020). In addition, very little

research has been conducted in Indonesia to find a relationship between blood type and mortality of COVID-19 patients (Liu *et al.*, 2021). However, there is increased interest in the relationship between blood type, and the risk of infection. Everyone agrees that individuals differ from one another, but it is rare for people to be able to predict whether a person's blood type makeup makes them more or less likely to contract an infection when exposed to viruses (Kim *et al.*, 2021). The purpose of this study was to assess the mortality of COVID-19 infected patients with different ABO blood types.

Materials and Methods

Study design and research sample

This study used a retrospective cohort. The research sample was COVID-19 patients who were in Dr. M. Djamil Hospital Padang, Indonesia. The research was conducted from January to November 2022. There were 93 total samples in this study. Convenience sampling was used as the sampling method in this study. Patients with COVID-19 with moderate to severe clinical severity and thoroughly documented information related to research variables met the inclusion criteria for this study.

Operational definition

Blood type was the study's independent variable (A, B, AB, and O) (Rana *et al.*, 2021). The dependent variable was COVID-19 patient mortality (death, and life) (Sjögren *et al.*, 2021).

Research ethics approval

The Dr. M. Djamil Hospital Padang research ethics committee approved this study after conducting an ethical review (LB.02.02/5.7/192/2022).

Data analysis

Research variables in categorical research are provided as frequency and percentage. While numeric variables are presented in the form of mean \pm SD or median (min-max). The Mann-Whitney test and the Chi-square test were used in the bivariate analysis. The data were analyzed using the SPSS version 21.0 program, and a p-value < 0.05 was considered significant.

Results

Table 1 shows subject characteristics.

Table 1: Subject characteristics.

| Characteristics | Mortality | | p-value |
|---|---------------------------|-------------------------|----------------------|
| | Death (n=27) | Life (n=66) | |
| Sex, f(%) | | | 0.226 ^a |
| Male | 21 (33.9) | 41 (66.1) | |
| Female | 6 (19.4) | 25 (80.6) | |
| Age (years), median (min-max) | 59 (21-79) | 56 (20-83) | 0.249 ^b |
| BMI (kg/m²), median (min-max) | 25.15 (15.82-76.10) | 24.80 (17.96-55.51) | 0.691 ^b |
| Clinical severity, f(%) | | | <0.001 ^{a*} |
| Moderate | 1 (2.0) | 49 (98.0) | |
| Severe | 22 (61.1) | 14 (38.9) | |
| Critical | 4 (57.1) | 3 (42.9) | |
| Laboratory examination, median (min-max) | | | |
| Hb (gr/dL) | 10.95 (4.4-17.4) | 12.00 (4.0-15.7) | 0.482 ^b |
| Ht (%) | 28.50 (6-53) | 36.00 (15-8,150) | 0.114 ^b |
| Leukocytes (/mm ³) | 2,240.50 (66-47,450) | 1,400.00 (7-23,160) | 0.365 ^b |
| Platelets | 191,000 (229-652,000) | 194,000 (44-650,000) | 0.722 ^b |
| D-Dimer (ng/mL) | 4,435.00 (1,039-10,000) | 777.00 (157-10,000) | <0.001 ^{b*} |
| Procalcitonin (ng/mL) | 0.74 (0.05-171) | 0.27 (0.05-171.42) | 0.092 ^b |
| IL-6 (pg/mL) | 262.50 (12.20-4,599.00) | 34.40 (1.50-600.00) | <0.001 ^{b*} |
| Ferritin (ng/mL) | 1,179.58 (12.40-2,000.00) | 710.00 (27.09-2,000.00) | <0.021 ^{b*} |
| SpO2 (%) | 90.00 (48-99) | 96.00 (33-99) | <0.001 ^{b*} |
| Number of comorbid, f(%) | | | 0.009 ^{a*} |
| None | 3 (14.3) | 18 (85.7) | |
| 1 | 2 (10.5) | 17 (89.5) | |
| > 1 | 22 (41.5) | 31 (58.5) | |

*p<0.05 considered significant; a, Chi-square test; b, Mann-whitney test

Table 1 (above) shows IL-6 levels, ferritin, SpO2 values, PCT levels, D-Dimer, clinical severity, and the number of comorbidities associated with mortality in COVID-19 patients hospitalized ($p < 0.05$).

The association of blood type and mortality of COVID-19 are presented in Table 2 and Figure 1.

Table 2: Association of blood type and mortality of COVID-19.

| Obese | Mortality | | p-value | OR (95% CI) |
|-------|-----------------------|----------------------|---------------------|-------------------|
| | Death (f/%) (n=27) | Life (f/%) (n=66) | | |
| A | 5 (13.9) | 31 (86.1) | 0.543 ^a | 0.19 (0.06-0.64) |
| B | 5 (26.3) | 14 (73.7) | 0.054 ^a | 2.21 (0.55-8.89) |
| AB | 5 (41.7) | 7 (58.3) | 0.021 ^{*a} | 4.43 (1.01-19.58) |
| O | 12 (46.2) | 14 (53.8) | 0.009 ^{*a} | 5.31 (1.57-17.98) |

* $p < 0.05$ considered significant; a, Chi-square test

Table 2 shows the percentage of deaths of COVID-19 patients was higher for blood group O (46.2%), followed by AB (41.7%), B (26.3%), and A (13.9%). There was a relationship between blood type and mortality in hospitalized COVID-19 patients ($p < 0.05$), where blood type O had the highest risk (OR = 5.31, 95% CI 1.57-17.98) followed by blood type AB (OR = 4.43, 95% CI 1.01-19.58).




Figure 1: Forest plot blood type and mortality of COVID-19.

Discussion

The results of this study indicate that the percentage mortality of COVID-19 patients was significantly higher for blood group O (46.2%), followed by blood group AB (41.7%), blood group B (26.3%) and blood group A (13.9%), respectively. There was a relationship between blood type and mortality in hospitalized COVID-19 patients, where blood type O had the highest risk (OR = 5.31) followed by blood type AB (OR = 4.43).

A previous study has stated that blood type is not associated with the risk of intubation or death in COVID-19 patients. Patients with blood types B and AB are more at risk of experiencing COVID-19 infection (Latz *et al.*, 2020). According to another study, COVID-19 patients had higher prevalences of blood types A and AB. Patients with blood categories A and AB reported delayed seroconversion despite the fact that ABO blood type was not related to presentation or recovery times for COVID-19 (Mahmud *et al.*, 2021).

Apart from anti-A antibodies, the link between group A and severe COVID-19 is increased activity of angiotensin-converting enzyme 1 (ACE-1), with a tendency for cardiovascular complications (Gasso *et al.*, 2014). The severe outcome could also be explained by the higher levels of von Willebrand Factor (vWF) and factor VIII in group A individuals. This increases the risk of thromboembolic disease and the severity of COVID-19 which can lead to death (Dai, 2020).

An individual's blood has a unique characteristic known as a blood type. Because the red blood cell membrane's surface contains a variety of various types of proteins and carbohydrates (Cooling, 2015). Through a

variety of processes, blood group antigens can affect the likelihood of developing a disease. These include acting as immune system modifiers in the form of anti-ABO antibodies and acting as immune system receptors or shams for pathogenic pathogens (Leaf *et al.*, 2020).

Previous studies identified inconsistent results, but it did discover certain tendencies that might point to a blood type-related greater vulnerability to COVID-19 infection or to a blood type-related protective effect for certain Rh-negative blood types (Rana *et al.*, 2021; Miotto *et al.*, 2021). COVID-19 is not only at risk by blood type but many other factors, including age or pre-existing medical disorders, are likely to have a larger, dominant role in defining personal risk from COVID-19, regardless of whether a particular blood type is linked to a higher risk of catching COVID-19 and developing severe disease (Pendur *et al.*, 2021; Djanas *et al.*, 2021).

The strength of this research is that it is the first study conducted to examine the relationship between blood type and death in COVID-19 patients treated in an Indonesian hospital. The limitations of this study were that the use of a retrospective cohort study in this study was not fully able to minimize bias, so a cohort study was needed to explain the causality that occurred. Apart from that, because this study only involved one referral hospital in Indonesia, further research is needed on several referral hospitals in Indonesia, so that the results can be representative of the population. According to another study, COVID-19 patients had higher prevalences of blood types A and AB. Patients with blood categories A and AB reported delayed seroconversion despite the fact that ABO blood type was not related to presentation or recovery times for COVID-19.

The implication of this study according to the study's findings, COVID-19 patients who have blood types O and AB are more likely to die or suffer other complications. Furthermore, more research is required to comprehend the molecular pathways through which blood groups may influence vulnerability to COVID-19 infection and, ultimately, to create treatments for viral infections and illnesses. Prioritizing patient treatment should be done by healthcare professionals based on the authors' advice to blood type patients with COVID-19 before treating them.

Conclusion

This study identified the relationship between blood type and death in COVID-19 patients who were hospitalized, where blood type O had the highest risk followed by blood type AB. This study can help with the therapeutic management of COVID-19 patients based on blood type so as to reduce the poor prognosis.

Acknowledgements

The authors of this article would like to thank all the study participants, as well as Universitas Andalas for the grant research granted them by the institution.

Conflict of interest statement

The authors declare that there is conflict of interest associated with this study.

References

1. Almazeedi, S., Al-Youha, S., Jamal, M. H., Al-Haddad, M., Al-Muhaini, A., Al-Ghimlas, F., and Al-Sabah, S. (2020). Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait. *EclinicalMedicine*, 24: 100448.
2. Belali T. M. (2022). Distribution of ABO and Rhesus Types in the Northern Asir Region in Saudi Arabia. *Journal of Blood Medicine*, 13: 643–648.
3. Cheng, Y., Cheng, G., Chui, C. H., Lau, F. Y., Chan, P. K., Ng, M. H., Sung, J. J., and Wong, R. S. (2005). ABO blood group and susceptibility to severe acute respiratory syndrome. *Journal of American Medical Association*, 293(12): 1450–1451.
4. Cooling L. (2015). Blood Groups in Infection and Host Susceptibility. *Clinical Microbiology Reviews*, 28(3): 801–870.
5. Dai X. (2020). ABO blood group predisposes to COVID-19 severity and cardiovascular diseases. *European Journal of Preventive Cardiology*, 27(13): 1436–1437.
6. Djanas, D., Yusirwan, Y., Martini, R. D., Rahmadian, R., Putra, H., Zanir, A., Syahrial, S., Nindrea, R. D. (2021). Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia. *Data in Brief*, 36: 107098.
7. Elnady, H. G., Abdel Samie, O. M., Saleh, M. T., Sherif, L. S., Abdalmoneam, N., Kholoussi, N. M., Kholoussi, S. M., and El-Taweel, A. N. (2017). ABO blood grouping in Egyptian children with rotavirus gastroenteritis. *Przegląd Gastroenterologiczny*, 12(3): 175–180.
8. Fan, Q., Zhang, W., Li, B., Li, D. J., Zhang, J., and Zhao, F. (2020). Association Between ABO Blood Group System and COVID-19 Susceptibility in Wuhan. *Frontiers in Cellular and Infection Microbiology*, 10: 404.
9. Gassó, P., Ritter, M. A., Mas, S., and Lafuente, A. (2014). Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity. *Journal of the Renin-Angiotensin-Aldosterone System*, 15(4): 580–584.

10. Göker, H., Aladağ Karakulak, E., Demiroğlu, H., Ayaz Ceylan, Ç. M., Büyükaşık, Y., Inkaya, A. Ç., Aksu, S., Sayinalp, N., Haznedaroğlu, I. C., Uzun, Ö., Akova, M., Özcebe, O. I., and Ünal, S. (2020). The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. *Turkish Journal of Medical Sciences*, 50(4): 679–683.
11. Hikmawati, I., and Setiyabudi, R. (2021). Epidemiology of COVID-19 in Indonesia: common source and propagated source as a cause for outbreaks. *Journal of Infection in Developing Countries*, 15(5): 646–652.
12. Kim, Y., Latz, C. A., DeCarlo, C. S., Lee, S., Png, C. Y. M., Kibrik, P., Sung, E., Alabi, O., and Dua, A. (2021). Relationship between blood type and outcomes following COVID-19 infection. *Seminars in Vascular Surgery*, 34(3): 125–131.
13. Latz, C. A., DeCarlo, C., Boitano, L., Png, C. Y. M., Patell, R., Conrad, M. F., Eagleton, M., & Dua, A. (2020). Blood type and outcomes in patients with COVID-19. *Annals of Hematology*, 99(9): 2113–2118.
14. Leaf, R. K., Al-Samkari, H., Brenner, S. K., Gupta, S., and Leaf, D. E. (2020). ABO phenotype and death in critically ill patients with COVID-19. *British Journal of Haematology*, 190(4): e204–e208.
15. Liu, N., Zhang, T., Ma, L., Zhang, H., Wang, H., Wei, W., Pei, H., and Li, H. (2021). The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. *Blood Reviews*, 48: 100785.
16. Mahmud, R., Rassel, M. A., Monayem, F. B., Sayeed, S. K. J. B., Islam, M. S., Islam, M. M., Yusuf, M. A., Rahman, S., Islam, K. M. N., Mahmud, I., Hossain, M. Z., Chowdhury, A. H., Kabir, A. K. M. H., Ahmed, K. G. U., and Rahman, M. M. (2021). Association of ABO blood groups with presentation and outcomes of confirmed SARS CoV-2 infection: A prospective study in the largest COVID-19 dedicated hospital in Bangladesh. *PLoS One*, 16(4): e0249252.
17. Miotto, M., Di Rienzo, L., Gosti, G., Milanetti, E., and Ruocco, G. (2021). Does blood type affect the COVID-19 infection pattern?. *PLoS One*, 16(5): e0251535.
18. Mohammadali, F., and Pourfathollah, A. (2014). Association of ABO and Rh Blood Groups to Blood-Borne Infections among Blood Donors in Tehran-Iran. *Iranian Journal of Public Health*, 43(7): 981–989.
19. Murugananthan, K., Subramaniyam, S., Kumanan, T., Owens, L., Ketheesan, N., and Noordeen, F. (2018). Blood group AB is associated with severe forms of dengue virus infection. *Virus Disease*, 29(1): 103–105.
20. Pendu, J. L., Breiman, A., Rocher, J., Dion, M., and Ruvoën-Clouet, N. (2021). ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data. *Viruses*, 13(2), 160: 1-20.
21. Rana, R., Ranjan, V., and Kumar, N. (2021). Association of ABO and Rh Blood Group in Susceptibility, Severity, and Mortality of Coronavirus Disease 2019: A Hospital-Based Study From Delhi, India. *Frontiers in Cellular and Infection Microbiology*, 11: 767771.
22. Sjögren, L., Stenberg, E., Thuccani, M., Martikainen, J., Rylander, C., Wallenius, V., Olbers, T., and Kindblom, J. M. (2021). Impact of obesity on intensive care outcomes in patients with COVID-19 in Sweden-A cohort study. *PLoS One*, 16(10): e0257891.
23. Velavan, T. P., and Meyer, C. G. (2020). The COVID-19 epidemic. *Tropical Medicine and International Health*, 25(3): 278–280.
24. Zhao, J., Yang, Y., Huang, H., Li, D., Gu, D., Lu, X., Zhang, Z., Liu, L., Liu, T., Liu, Y., He, Y., Sun, B., Wei, M., Yang, G., Wang, X., Zhang, L., Zhou, X., Xing, M., and Wang, P. G. (2021). Relationship between the ABO Blood Group and the Coronavirus Disease 2019 (COVID-19) Susceptibility. *Clinical Infectious Diseases; an Official Publication of the Infectious Diseases Society of America*, 73(2): 328–331.